- Home
- PD vs ATAI Comparison
PD vs ATAI Comparison
Compare PD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PD | ATAI |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PD | ATAI |
|---|---|---|
| Price | $12.55 | $4.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $17.10 | $14.33 |
| AVG Volume (30 Days) | 1.6M | ★ 3.4M |
| Earning Date | 11-25-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $489,207,000.00 | $3,018,000.00 |
| Revenue This Year | $8.16 | $943.18 |
| Revenue Next Year | $3.88 | N/A |
| P/E Ratio | $7.77 | ★ N/A |
| Revenue Growth | 7.01 | ★ 811.78 |
| 52 Week Low | $11.13 | $1.15 |
| 52 Week High | $20.00 | $6.75 |
Technical Indicators
Market Signals| Indicator | PD | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 45.43 |
| Support Level | $12.06 | $3.64 |
| Resistance Level | $12.77 | $4.14 |
| Average True Range (ATR) | 0.38 | 0.25 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 35.06 | 32.87 |
Price Performance
Historical ComparisonAbout PD PagerDuty Inc.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.